Low-dose aspirin has been considered useful for the management of heart disease and ischemic stroke, as well as for the primary prevention of cardiovascular disease and even cancer. Now the evidence is accumulating that low-dose aspirin used as an adjuvant treatment of cancer is associated with an increased survival and a reduction in metastatic spread. A recent meta-analysis of published studies that included low-dose aspirin in cancer has proven this posit. ⠀⠀⠀⠀⠀⠀⠀⠀⠀ ⠀⠀⠀⠀⠀⠀⠀⠀⠀ ⠀⠀⠀⠀⠀⠀⠀⠀⠀ This review included meta-analyses of 71 studies with a total of over 120 thousand patients taking aspirin. Pooled estimates from 29 observational studies with aspirin in colorectal cancer (CRC) demonstrated an overall Hazard Ratio for aspirin and CRC mortality as 0.72, indicating a 28% reduction. Similar estimates from 14 observational studies on breast cancer mortality gave an overall HR of 0.69, indicating a 31% reduction. For prostate cancer, 16 studies reported prostate cancer mortality HR to be 0.87, indicating a 13% reduction. Ten studies gave evidence of a reduction in metastatic spread; four with a pooled Odds Ratio of 0.31, indicating a 69% reduction and five with an OR of 0.79, indicating a 21% reduction. ⠀⠀⠀⠀⠀⠀⠀⠀⠀ ⠀⠀⠀⠀⠀⠀⠀⠀⠀ This evidence merits wide discussion regarding whether or not it is adequate to justify the recommendation of low-dose therapeutic aspirin, and if it is, for which cancers? ⠀⠀⠀⠀⠀⠀⠀⠀⠀ Source: Elwood PC, et al. PLoS ONE. 2018. Image credit: Pexels